innoscripta SE/€1INN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About innoscripta SE

Innoscripta SE is a German software company specializing in cloud-based compliance solutions for research and development (R&D) tax credits and project management. Its primary product is a Software-as-a-Service (SaaS) platform that digitizes R&D workflows, assisting companies in identifying, validating, and managing R&D projects while ensuring compliant documentation for tax incentives. Founded in 2012 and headquartered in Munich, Germany, Innoscripta serves over 2,000 clients across more than twenty industries. The company operates on multi-year exclusive contracts, typically around three years, with most automatically renewed, generating revenue through commissions based on a percentage of clients' recoverable R&D costs. Innoscripta's scalable platform is designed for easy adoption across various countries and industries, supporting its growth strategy focused on international expansion and product development. (,)

Ticker

€1INN
Sector
Information Technology

Primary listing

XETRA

Industry

Software
Headquarters
Munich, Germany

Employees

477

ISIN

DE000A40QVM8
Website
innoscripta.com

innoscripta SE Metrics

BasicAdvanced
€1B
31.27
€3.27
-
-

Bulls say / Bears say

Innoscripta SE has demonstrated strong financial performance, with revenues increasing from EUR 27.3 million in 2022 to EUR 64.7 million in 2024, and an EBIT margin rising to 57.6% in 2024, indicating robust profitability and growth potential. (webdisclosure.com)
The company's successful IPO on May 23, 2025, with an initial share price of EUR 120 and a market capitalization of EUR 1.2 billion, reflects strong investor confidence and provides capital for further expansion. (boerse-frankfurt.de)
Innoscripta's low customer churn rate of less than 2% over the past three years and a customer base exceeding 1,700 across more than twenty industries suggest a resilient and loyal clientele, supporting sustained revenue streams. (webdisclosure.com)
The company's rapid growth may face challenges in maintaining its high EBIT margins as it scales operations and enters new markets, potentially leading to increased operational costs and margin compression. (webdisclosure.com)
Innoscripta's reliance on the German market for a significant portion of its revenue exposes it to regional economic fluctuations and regulatory changes, which could adversely affect its financial performance. (webdisclosure.com)
The company's recent IPO and subsequent share price volatility, with a decline from the initial EUR 120 to EUR 88 by June 4, 2025, may indicate market skepticism about its valuation and future growth prospects. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €1INN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs